Last reviewed · How we verify
hydrochloride hydromorphone + flurbiprofen axetil
This combination drug provides opioid analgesia via hydromorphone and anti-inflammatory pain relief via flurbiprofen axetil to manage moderate to severe pain.
This combination drug provides opioid analgesia via hydromorphone and anti-inflammatory pain relief via flurbiprofen axetil to manage moderate to severe pain. Used for Moderate to severe acute pain management.
At a glance
| Generic name | hydrochloride hydromorphone + flurbiprofen axetil |
|---|---|
| Sponsor | First Affiliated Hospital, Sun Yat-Sen University |
| Drug class | Opioid analgesic + NSAID combination |
| Target | Mu-opioid receptor (hydromorphone); COX-1/COX-2 (flurbiprofen axetil) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydromorphone is a mu-opioid receptor agonist that provides potent analgesia by binding to opioid receptors in the central nervous system. Flurbiprofen axetil is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis, providing anti-inflammatory and analgesic effects. The combination targets pain through complementary mechanisms—opioid and NSAID—to enhance analgesia while potentially reducing required opioid doses.
Approved indications
- Moderate to severe acute pain management
Common side effects
- Nausea
- Dizziness
- Constipation
- Gastrointestinal upset
- Respiratory depression
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: